Molecular and clinical implementations of ovarian cancer mouse avatar models

Amira A. Zayed, Sumithra J Mandrekar, Paul Haluska

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Innovation in oncology drug development has been hindered by lack of preclinical models that reliably predict clinical activity of novel therapies in cancer patients. Increasing desire for individualize treatment of patients with cancer has led to an increase in the use of patient-derived xenografts (PDX) engrafted into immune-compromised mice for preclinical modeling. Large numbers of tumor-specific PDX models have been established and proved to be powerful tools in pre-clinical testing. A subset of PDXs, referred to as Avatars, establish tumors in an orthotopic and treatment naïve fashion that may represent the most clinical relevant model of individual human cancers. This review will discuss ovarian cancer (OC) PDX models demonstrating the opportunities and limitations of these models in cancer drug development, and describe concepts of clinical trials design in Avatar guided therapy.

Original languageEnglish (US)
Article number30
JournalChinese Clinical Oncology
Volume4
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Ovarian Neoplasms
Heterografts
Neoplasms
Therapeutics
Pharmaceutical Preparations
Clinical Trials

Keywords

  • Clinical trial design
  • Model systems
  • Ovarian cancer (OC)
  • Patient-derived xenografts (PDX)
  • Personalized medicine
  • Xenograft models

ASJC Scopus subject areas

  • Oncology

Cite this

Molecular and clinical implementations of ovarian cancer mouse avatar models. / Zayed, Amira A.; Mandrekar, Sumithra J; Haluska, Paul.

In: Chinese Clinical Oncology, Vol. 4, No. 3, 30, 2015.

Research output: Contribution to journalArticle

@article{e2a44d29ee654539a7bbbc0ed8b874e5,
title = "Molecular and clinical implementations of ovarian cancer mouse avatar models",
abstract = "Innovation in oncology drug development has been hindered by lack of preclinical models that reliably predict clinical activity of novel therapies in cancer patients. Increasing desire for individualize treatment of patients with cancer has led to an increase in the use of patient-derived xenografts (PDX) engrafted into immune-compromised mice for preclinical modeling. Large numbers of tumor-specific PDX models have been established and proved to be powerful tools in pre-clinical testing. A subset of PDXs, referred to as Avatars, establish tumors in an orthotopic and treatment na{\"i}ve fashion that may represent the most clinical relevant model of individual human cancers. This review will discuss ovarian cancer (OC) PDX models demonstrating the opportunities and limitations of these models in cancer drug development, and describe concepts of clinical trials design in Avatar guided therapy.",
keywords = "Clinical trial design, Model systems, Ovarian cancer (OC), Patient-derived xenografts (PDX), Personalized medicine, Xenograft models",
author = "Zayed, {Amira A.} and Mandrekar, {Sumithra J} and Paul Haluska",
year = "2015",
doi = "10.3978/j.issn.2304-3865.2015.04.01",
language = "English (US)",
volume = "4",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

TY - JOUR

T1 - Molecular and clinical implementations of ovarian cancer mouse avatar models

AU - Zayed, Amira A.

AU - Mandrekar, Sumithra J

AU - Haluska, Paul

PY - 2015

Y1 - 2015

N2 - Innovation in oncology drug development has been hindered by lack of preclinical models that reliably predict clinical activity of novel therapies in cancer patients. Increasing desire for individualize treatment of patients with cancer has led to an increase in the use of patient-derived xenografts (PDX) engrafted into immune-compromised mice for preclinical modeling. Large numbers of tumor-specific PDX models have been established and proved to be powerful tools in pre-clinical testing. A subset of PDXs, referred to as Avatars, establish tumors in an orthotopic and treatment naïve fashion that may represent the most clinical relevant model of individual human cancers. This review will discuss ovarian cancer (OC) PDX models demonstrating the opportunities and limitations of these models in cancer drug development, and describe concepts of clinical trials design in Avatar guided therapy.

AB - Innovation in oncology drug development has been hindered by lack of preclinical models that reliably predict clinical activity of novel therapies in cancer patients. Increasing desire for individualize treatment of patients with cancer has led to an increase in the use of patient-derived xenografts (PDX) engrafted into immune-compromised mice for preclinical modeling. Large numbers of tumor-specific PDX models have been established and proved to be powerful tools in pre-clinical testing. A subset of PDXs, referred to as Avatars, establish tumors in an orthotopic and treatment naïve fashion that may represent the most clinical relevant model of individual human cancers. This review will discuss ovarian cancer (OC) PDX models demonstrating the opportunities and limitations of these models in cancer drug development, and describe concepts of clinical trials design in Avatar guided therapy.

KW - Clinical trial design

KW - Model systems

KW - Ovarian cancer (OC)

KW - Patient-derived xenografts (PDX)

KW - Personalized medicine

KW - Xenograft models

UR - http://www.scopus.com/inward/record.url?scp=84960393736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960393736&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2304-3865.2015.04.01

DO - 10.3978/j.issn.2304-3865.2015.04.01

M3 - Article

VL - 4

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 3

M1 - 30

ER -